Evidence Hub

Economic Impact of Biologics for Severe Asthma: A Case Series of 14 Patients From Northern Malaysia

A. Alaga, Izzatul Nadzirah Ismail

Respirology Case Reports, 2025

1 citation

Abstract

There remains a paucity of evidence from Asia on the cost‐effectiveness of biologics for severe asthma. This pilot cost‐offset analysis aims to evaluate the economic impact of adding biologics (omalizumab or benralizumab) to severe asthma standard care as a proof of concept for its cost‐effectiveness, and to assess improvement in exacerbation rates and asthma control. Fourteen patients from the Severe Asthma Registry of Hospital Sultanah Bahiyah, Kedah who received biologics for at least 12 months from January 2018 to December 2024 were included. The economic impact of biologic treatment was evaluated by comparing the cost of biologic administration with the potential savings from reduced exacerbations requiring emergency department visits and hospital admission. Cost savings were observed with biologics, alongside reduced exacerbation and improved asthma control in real‐world settings. Future research could explore a full cost‐effectiveness analysis and a budget impact analysis to inform strategic pricing and reimbursement decisions.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free